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PREAMBLE
The voluntary withdrawal of cerivastatin (Baycol) from the
U.S. market on August 8, 2001, by the manufacturer, in
agreement with the Food and Drug Administration (FDA),
has prompted concern on the part of physicians and patients
regarding the safety of the cholesterol-lowering class of
drugs called HMG CoA reductase inhibitors, more com-
monly known as “statins.” This American College of Car-
diology/American Heart Association/National Heart, Lung
and Blood Institute (ACC/AHA/NHLBI) Clinical Advi-
sory is intended to summarize for professionals the current
understanding of statin use, focused on myopathy, and to
provide updated recommendations for the appropriate use
of statins, including cautions, contraindications, and safety
monitoring for statin therapy. Its purpose is not to discour-
age the appropriate use of statins, which have life-saving
potential in properly selected patients, particularly those
with established coronary heart disease (CHD) and others
at high risk for developing CHD. Included are recent
myopathy information compiled by the FDA, information
from clinical trials, and summaries from the recently re-
leased report of the Adult Treatment Panel III (ATP III) of
the National Cholesterol Education Program (NCEP) (1).
INTRODUCTION
In the literature, the general terminology used to describe
muscle toxicity is inconsistent. Therefore, for the purpose of
this document, the following terms are used as defined here:
Myopathy—a general term referring to any disease of mus-
cles; myopathies can be acquired or inherited and can occur
at birth or later in life (Source: NINDS Myopathy Page-
http://accessible.ninds.nih.gov/health_and_medical/
disorders/myopathy.htm). Myalgia—muscle ache or weak-
ness without creatine kinase (CK) elevation. Myositis—muscle
symptoms with increased CK levels. Rhabdomyolysis—
muscle symptoms with marked CK elevation (typically
substantially greater than 10 times the upper limit of normal
[ULN]) and with creatinine elevation (usually with brown
urine and urinary myoglobin).
Statins are powerful low-density lipoprotein (LDL)-
lowering drugs that are widely used in clinical practice.
Results from clinical trials with a mean duration of 5.4 years
have demonstrated a decrease in CHD and total mortality,
reductions in myocardial infarctions, revascularization pro-
cedures, stroke, and peripheral vascular disease (2–8). These
trials documented a benefit in both men and women,
primarily in middle-aged and older persons treated in the
setting of either primary or secondary prevention. More
than 50,000 individuals have been randomized to either a
placebo or statin in these trials, and no serious morbidity or
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increase in mortality was observed in the drug treatment
groups. These agents reduce the risk of essentially every
clinical manifestation of the atherosclerotic process; they are
easy to administer, with good patient acceptance. There are
very few drug to drug interactions. Although the experience
with the safety of statin therapy outside of clinical trials has
not been fully reported, it is reasonable to suspect that the
incidence of side effects may be higher in clinical situations
where patients are not monitored as closely as they are in
clinical trials (9).
The NCEP has published updated guidelines for treat-
ment of high blood cholesterol (Adult Treatment Panel III
report) (1). These guidelines are endorsed by the ACC and
AHA. They identify elevated LDL cholesterol as the
primary target of therapy and establish goals for LDL
cholesterol that depend on a patient’s risk status. The Adult
Treatment Panel III report was able to apply rigorous
clinical trial evidence to identify additional high-risk indi-
viduals for treatment, greatly expanding the number of
patients who are candidates for these drugs. These include
patients with established CHD, other forms of atheroscle-
rotic disease, diabetes mellitus, multiple risk factors impart-
ing high risk, and severe hypercholesterolemia. In many
patients, relatively high doses of statins will be required to
achieve LDL cholesterol goals of therapy. In addition, for
patients with high triglycerides, non–high-density lipopro-
tein (HDL) cholesterol (LDL  VLDL [very low density
lipoprotein] cholesterol) has been identified as a secondary
target of therapy. To achieve the non–HDL cholesterol
goal, many patients will require statin therapy as well. This
broad expansion of statin use will require that increased
attention be given to every aspect of statin therapy (i.e.,
efficacy, safety, and cost-effectiveness).
In view of the demonstrated safety of these agents, both
medical professionals and the public were surprised by the
recent withdrawal of a relatively new statin, cerivastatin
(Baycol), from the market. Cerivastatin was first approved
for use in the U.S. in 1997. In August 2001, the manufac-
turer, Bayer AG, announced the withdrawal of all dosages
of its cholesterol-lowering drug with the brand names
Baycol/Lipobay (cerivastatin) because of increasingly fre-
quent reports of serious myopathy, including severe and
life-threatening rhabdomyolysis. Rhabdomyolysis was re-
ported most frequently when cerivastatin was used at higher
doses and, particularly, in combination with another lipid-
lowering drug, gemfibrozil (LOPID and generics). At the
time of withdrawal, the FDA had received reports of 31
U.S. deaths due to severe rhabdomyolysis associated with
the use of cerivastatin, 12 of which involved concomitant
gemfibrozil use (http://www.fda.gov/cder/drug/infopage/
baycol/). Subsequently, the Wall Street Journal (1/21/02,
pg. A10) reported that Bayer AG had indicated that as
many as 100 deaths have been linked to Baycol. The FDA
reports that the rate of fatal rhabdomyolysis is 16 to 80
times more frequent for cerivastatin as compared to any
other statin (10).
INCIDENCE OF ADVERSE EVENTS
The statins are well tolerated by most persons. Elevated
hepatic transaminases generally occur in 0.5% to 2.0% of
cases and are dose-dependent (11,12). Whether transami-
nase elevation with statin therapy constitutes true hepato-
toxicity has not been determined. Progression to liver failure
specifically due to statins is exceedingly rare if it ever occurs
(13). Reversal of transaminase elevation is frequently noted
with a reduction in dose, and elevations do not often recur
with either re-challenge or selection of another statin
(14,15). Cholestasis and active liver disease are listed as
contraindications to statin use; however, no specific evi-
dence exists showing exacerbation of liver disease by statins.
Furthermore, statins have not been shown to worsen the
outcome in persons with chronic transaminase elevations
due to hepatitis B or C, and treatment of hyperlipidemia
may actually improve transaminase elevations in individuals
with fatty liver (16). An observational study (16a) has
suggested a rare association of statin use with polyneurop-
athy. This has not been found in the large blinded random-
ized controlled trials.
The ability of statins to produce myopathy under some
circumstances is well established. A common complaint is
non-specific muscle aches or joint pains that are generally
not associated with significant increases in creatine kinase.
In placebo-controlled trials, the incidence of these com-
plaints (generally reported as about 5%) is similar between
placebo and active drug therapy, suggesting they may not be
drug-related (12–17). Nonetheless, in some patients, the
temporal association with statin therapy is strong enough to
implicate these drugs as a cause of these complaints. Other
patients can have mild-to-moderate elevations of creatine
kinase without muscle complaints. Again, elevations may be
non-specific, but a statin effect often cannot be ruled out.
It is rare that patients treated with a statin exhibit severe
myositis characterized by muscle aches, soreness or weak-
ness and associated with elevated creatine kinase levels,
generally greater than 10 times the ULN. In this setting,
failure to discontinue drug therapy can lead to rhabdomy-
olysis, myoglobinuria, and acute renal necrosis (18). Myo-
sitis is most likely to occur in persons who have complex
medical problems and/or who are taking multiple medica-
tions. It may rarely occur with statin monotherapy, but it
occurs more frequently when statins are used in combina-
tion with a variety of medications, including cyclosporine,
fibrates, macrolide antibiotics, certain antifungal drugs, and
niacin (19–21). Some of the drug to drug interactions
involve specific interactions with the cytochrome P-450
drug-metabolizing system, especially those involving the
3A4 isozyme (22,23). The combination of statins with a
fibrate is attractive for persons who have both high serum
cholesterol and high triglycerides or for those who continue
to have elevated triglycerides after reaching their LDL-
cholesterol target on statin therapy. However, there may be
a concern about an increased danger of developing myop-
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athy with this combination. In the past, this combination
was thought to be “contraindicated” because of the potential
danger of myopathy. More recently, it has been used
increasingly with apparent safety in the majority of persons.
This combination is now presented by the ATP III report as
an option, with careful monitoring, for some forms of
dyslipidemia.
The FDA report comparing the rate of fatal rhabdomy-
olsis among different statins is of considerable importance
(10). The FDA performed a detailed review of all reports of
fatal rhabdomyolysis in their Adverse Event Reporting
System and obtained the number of prescriptions dispensed
since marketing of each statin began in the U.S. Fatal
rhabdomyolysis was extremely rare (less than 1 death/
million prescriptions). As previously noted, the rate of fatal
rhabdomyolsis for cerivastatin was far greater than that for
other statins (16 to 80 times higher). Even after excluding
cases in which cerivastatin was administered with gemfibro-
zil, the reporting rate for fatal rhabdomyolysis with ceriv-
astatin monotherapy (1.9 deaths per million prescriptions)
was 10 to 50 times higher than for other statins. The FDA
report also noted that more than 60% of the fatal cases
with cerivastain were associated with use of the highest
dose (0.8 mg daily). The FDA notes that the data are
reporting rates, not incidence rates. Thus, statistically
“rigorous comparisons between drugs . . . are not recom-
mended” (10). Nevertheless, review of these data strongly
suggests that there were no clinically important differ-
ences in the rate of fatal complications among the five
statins now available in the U.S. (atorvastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin). Clinicians
should consider the rates of severe myopathy as equiva-
lent among all of these approved statins.
The following are summary comments reflecting current
experience with these issues:
● Statin therapy appears to carry a small but definite risk of
myopathy when used alone. According to several large
clinical trial databases, the incidence of severe myopathy
is reported to be 0.08% with lovastatin and simvastatin
(14,15). Elevations of CK greater than 10 times the ULN
have been reported in 0.09% of persons treated with
pravastatin. All currently marketed statins appear to have
a similar potential for causing this adverse effect.
● Fibrate treatment alone appears to be associated with
some (probably similar) risk of myopathy.
● Of the nearly 600 persons who have participated in
controlled clinical trials of a statin and fibrate combina-
tion, 1% have experienced a CK greater than 3 times the
ULN without muscle symptoms, and 1% have been
withdrawn from therapy because of muscle discomfort
(24–31). None of these findings were considered serious
by the trial investigators. No cases of rhabdomyolysis or
myoglobinuria have been encountered in these clinical
trials. The experience in these trials is predominantly
with lovastatin and gemfibrozil, but it is reasonable to
believe that the experiences with other statin-fibrate
combinations would be similar.
MECHANISM OF MYOPATHY
Because it occurs so rarely, little is known about the
fundamental mechanisms of statin-associated myopathy. It
has been suggested that statins lead to inhibited synthesis of
compounds arising from the synthetic pathway of choles-
terol. In theory, this could lead to ubiquinone (an essential
intracellular energy component) deficiency in muscle cell
mitochondria, disturbing normal cellular respiration and
causing adverse effects including rhabdomyolysis. Despite
in-vitro support for this concept (32,33), a human study of
six months of simvastatin treatment (20 mg per day) on
skeletal muscle concentrations of high-energy phosphates
and ubiquinone demonstrated that the muscle high-energy
phosphate and ubiquinone concentrations assayed after
simvastatin treatment were similar to those observed at
baseline and did not differ from values in control subjects
(34). No clinical study has yet provided support for the
hypothesis of diminished isoprenoid synthesis or energy
generation in muscle cells during statin therapy. Some
have proposed that statin interaction with the cyto-
chrome P-450 hepatic enzyme system might be related to
myopathy (22). Support for this concept comes, in part,
from the known enhanced toxicity when statins are
administered with agents sharing metabolism by the same
cytochrome isoforms. Finally, it has been shown that
exercise in combination with lovastatin produces greater
creatine kinase elevations than those produced by exercise
alone, suggesting that statins can exacerbate exercise-
induced skeletal muscle injury (35).
DIAGNOSIS
Routine laboratory monitoring of CK is of little value in the
absence of clinical signs or symptoms. Therefore, all persons
beginning to receive statins should be instructed to report
muscle discomfort or weakness or brown urine immediately,
which should then prompt a CK measurement.
MANAGEMENT
Baseline Measurements
Before initiating statin therapy, baseline measurements,
including a lipid and lipoprotein profile, that will be used to
follow the drug’s efficacy and safety should be documented.
Current labeling for all statins requires baseline measure-
ments of liver function, including alanine transferase and
aspartate transferase, although this is not agreed on by many
liver experts and will likely undergo review in the future.
Modest transaminase elevations (less than 3 times the
ULN) are not thought to represent a contraindication to
initiating, continuing, or advancing statin therapy, as long as
patients are carefully monitored. Many experts also favor,
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and the ATP III report recommends, baseline CK measure-
ment, reasoning that asymptomatic CK elevations are com-
mon and pre-treatment knowledge of this condition can aid
in later clinical decision making.
Monitoring for Adverse Reactions and Adjusting Therapy
Once therapy has been initiated, symptoms may appear at
any time. If myositis is present or strongly suspected, the
statin should be discontinued immediately. Several key
points should be kept in mind.
Obtain a CK measurement if the patient reports sugges-
tive muscle symptoms, and compare to CK blood level prior
to beginning therapy. Because hypothyroidism predisposes
to myopathy, a thyroid-stimulating hormone level should
also be obtained in any patient with muscle symptoms.
If the patient experiences muscle soreness, tenderness, or
pain, with or without CK elevations, rule out common
causes such as exercise or strenuous work. Advise modera-
tion in activity for persons who experience these symptoms
during combination therapy.
Discontinue statin therapy (or statin and niacin or fibrate
if the patient is on combination therapy) if a CK greater
than 10 times the ULN is encountered in a patient with
muscle soreness, tenderness, or pain.
If the patient experiences muscle soreness, tenderness, or
pain with either no CK elevation or a moderate elevation (3
to 10 times the ULN), follow the patient’s symptoms and
CK levels weekly until there is no longer medical concern or
symptoms worsen to the situation described previously (at
which point therapy should be discontinued). For patients
who develop muscle discomfort and/or weakness and who
also have progressive elevations of CK on serial measure-
ments, either a reduction of statin dose or a temporary
discontinuation may be prudent. A decision can then be
made whether or when to reinstitute statin therapy.
Asymptomatic Patients With CK Elevation
Prior to the withdrawal of cerivastatin, the ATP III report
did not recommend routine ongoing monitoring of CK in
asymptomatic patients. If a physician chooses to obtain CK
values in asymptomatic patients, particularly those on com-
bination therapy, and CKs are elevated to more than 10
times the ULN, strong consideration should be given to
stopping therapy. Following discontinuation, wait for symp-
toms to resolve and CK levels to return to normal before
reinitiating therapy with either drug and use a lower dose of
the drug(s) if possible.
Some asymptomatic patients will have moderate (i.e.,
between 3 and 10 times the ULN) CK elevations at
baseline, during treatment, or after a drug holiday. Such
patients can usually be treated with a statin without harm.
However, particularly careful monitoring of symptoms and
more frequent CK measurements are indicated.
PREVENTION
Increased Risk States for Statin-Associated Myopathy
Prevention of statin-associated myopathy can best be ac-
complished by attention to those factors that might increase
the risk for such myopathy:
● Advanced age (especially more than 80 years) in patients
(women more than men)
● Small body frame and frailty
● Multisystem disease (e.g., chronic renal insufficiency,
especially due to diabetes)
● Multiple medications
● Perioperative periods
● Specific concomitant medications or consumption as
listed below (check specific statin package insert for
warnings)
 Fibrates (especially gemfibrozil, but other fibrates too)
 Nicotinic acid (rarely)
 Cyclosporine
 Azole antifungals
 Itraconazole and ketoconazole
 Macrolide antibiotics
 Erythromycin and clarithromycin
 HIV protease inhibitors
 Nefazodone (antidepressant)
 Verapamil
 Amiodarone
 Large quantities of grapefruit juice (usually more than 1
quart per day)
 Alcohol abuse (independently predisposes to myop-
athy)
Clinical Precautions
Most myopathy associated with statins appears to occur in
patients who are at risk for the condition. For this reason,
physicians should be aware of several caveats when prescrib-
ing statin therapy. Myopathy is more likely to occur at
higher statin doses than at lower doses. For this reason,
doses should not exceed those required to attain the
ATP III goal of therapy. As a rule, statin therapy should
be employed more cautiously in older persons, particularly
older thin or frail women, but it is not contraindicated in
these or other high-risk patients. Among older persons,
those with multisystem disease apparently are at higher risk.
Patients with diabetes combined with chronic renal failure
also appear to be at higher risk for myopathy—such patients
should be monitored carefully. In several instances, myop-
athy has developed when patients were continued on statin
therapy during hospitalization for major surgery. Therefore,
it probably is prudent to withhold statins during such
periods.
Particular attention should be given to drug interactions
when employing statin therapy. Although the combination
of statin plus fibrate is accompanied by an increased danger
of myopathy, the use of moderate statin doses combined
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with fibrate appears to have a relatively low incidence of
myopathy, especially when used in persons without multi-
system disease or multiple medications. The combination of
statin plus nicotinic acid seemingly carries a lower risk for
myopathy than does statin plus fibrate. Finally, physicians
should be aware of the dangers of interactions of statins with
the other drugs previously listed. These combinations
should also be used with caution or avoided altogether.
Furthermore, it is important for clinicians prescribing st-
atins to make sure that their patients are aware of these
potential drug interactions, because in current practice, a
patient may receive prescriptions from many different care-
givers.
SUMMARY
Statin therapy holds great promise for reducing the inci-
dence of major coronary events, coronary procedures, and
stroke in high-risk patients. At present, this potential has
not been fully realized, because many patients at heightened
risk are not being treated with these drugs. There is a well
documented under-use of statins in clinical practice. Statins
have proven to be extremely safe in the vast majority of
patients receiving them. Few significant side effects were
observed in clinical trials, and post-marketing reports of
adverse events have been very limited when considered in
comparison to the very large number of persons safely
receiving these drugs. Even so, these drugs are not entirely
free of side effects, and as for all drugs, they should be used
appropriately and judiciously. This advisory encourages the
appropriate use of statins while pointing out the possibility
of side effects in certain patients. If statins are used with
appropriate caution in these selected patients, the likelihood
of developing clinically important myopathy should be
substantially reduced. (See Tables 1 and 2.)
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Baycol Information
FDA announced on August 8, 2001 that Bayer Pharmaceutical Division is voluntarily withdrawing
Baycol (cerivastatin) from the U.S. market because of reports of sometimes fatal rhabdomyolysis, a
severe muscle adverse reaction from this cholesterol-lowering (lipid-lowering) product. The FDA
agrees with and supports this decision.
Baycol Talk Paper (8/8/2001)l   
Baycol Questions and Answers (8/8/2001)l   
Dear Healthcare Professional Letter (8/8/2001)l   
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